基于triazolo[4,5-d]pyrimidin-5-amines的ERK3抑制剂未能证明对脂肪细胞功能的选择性影响
Andrei Belykh1, Izabela Hawro1, Katarzyna Kolczyńska-Matysiak1
1Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland.
Archives of biochemistry and biophysics
|November 22, 2023
概括
细胞外信号调节激酶3 (ERK3) 调节脂解,但测试的抑制剂显示非选择性作用. 这些化合物通过影响ERK3.3以外的多个点,影响代谢健康.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 细胞外信号调节激酶3 (ERK3),也称为MAPK6,是参与许多生理和病理过程的激酶.
- 准ERK3为癌症,肥胖和糖尿病等代谢障碍以及其他身体病理提供了潜在的治疗策略.
- ERK3是脂肪细胞中脂解的已知调节剂,使其成为代谢研究的关键目标.
研究的目的:
- 合成和评估三醇[4,5-d]胺-5-胺作为潜在的ERK3抑制剂.
- 评估这些化合物对细胞代谢状态的选择性和生物影响,特别是脂解.
- 研究ERK3抑制对脂解酶和相关蛋白质的直接和间接影响.
主要方法:
- 三种三醇[4,5-d]胺-5-氨基的合成.
- 利用各种脂肪细胞模型研究脂解.
- 采用基于机器学习的预测来识别合成化合物的潜在目标.
主要成果:
- 合成的化合物调节脂解,但它们的作用不仅仅取决于ERK3抑制.
- 发现ERK3不仅可以调节ATGL,还可以调节激素敏感脂酶 (HSL) 和单甘油脂酶 (MGL).
- ERK3还影响脂肪酸合成酶 (FASN) 和蛋白激酶cAMP激活的催化子单元α (PKACα) 的丰度.
- 机器学习预测揭示了测试化合物的广泛潜在目标,表明非选择性.
结论:
- 虽然测试的化合物在体外抑制了ERK3,但它们的生物效应是复杂的,并受到非目标相互作用的影响.
- 这些抑制剂对多个标的非选择性结合改变了ERK3抑制的生物结果.
- 需要进一步的研究来开发有选择性的ERK3抑制剂,用于代谢疾病和癌症的治疗应用.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
210
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
210
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
885
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
885
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


